

# 3rd Annual Southern California Genitourinary Cancer Research Forum

 [WELCOME](#) [GENERAL INFORMATION](#)

- [Important Reminders](#)
- [Conference Details: Location, Times, etc.](#)

 [CME INFORMATION](#)

- [CME Credit Information](#)
- [Instructions for Obtaining CME Credit](#)
  - *AMA PRA Category 1 Credit™*

 [E-SYLLABUS](#) [WIFI INFORMATION](#) [UPCOMING CONFERENCES](#) [ACKNOWLEDGMENT OF COMMERCIAL SUPPORT](#) [CORE COMPETENCIES INFORMATION SHEET](#) [DISCLOSURES](#) [CONFERENCE SCHEDULE](#) [CONFERENCE TASKS](#)

- [Link to Conference Evaluation](#)

## 3rd Annual Southern California Genitourinary Cancer Research Forum

*Welcome* to the 3rd Annual Southern California Genitourinary Cancer Research Forum, in Huntington Beach, CA!

On behalf of City of Hope and the Department of Continuing Medical Education, we would like to thank you for joining us for this educational activity.

Interest and input from our participants encouraged us to continue to expand the focus of this conference, incorporating requests and suggestions from attendees. The previous year of this conference was a great success, and we are happy to have you join us this year.

Our goal is to provide the desired information and skills which physicians and allied health care providers need in order to better serve their patient populations and research. Your thoughts are valuable and important, so please share them with us on the evaluation that will be emailed to you at the conclusion of the conference.

The link to the *Evaluation* can also be accessed under the **Conference Tasks** page of this handout.

Should you have any questions, please visit the conference staff at the registration desk.

For post-conference CME information, please contact:

City of Hope  
Department of Continuing Medical Education  
1500 E. Duarte Road  
Duarte, CA 91010  
[cme@coh.org](mailto:cme@coh.org)  
(626) 218-5622

## 3rd Annual Southern California Genitourinary Cancer Research Forum

### Contactless Registrant Sign-in:

You must confirm your attendance on the day of the conference.

You will be provided with a unique code to record your attendance. You will need to text in the attendance code to the City of Hope CME text-in number (626-314-7448). Registrant sign-in, can also be completed via QR Code.

To ensure you are ready for *Contactless Registrant Sign-in*:

1. Please be sure to have with you the cell phone (mobile) you registered in your CME Profile.  
**If you have not done so yet, confirm your mobile number (*you only have to do this once*)**

Log on to: <https://cme.cityofhope.org> Once logged on, click on "My Account" on the top right corner → Click on the "Edit" tab → then click on the "Mobile" tab:

- If mobile number is correct and you see the word "DONE!" simply close out the page. You are done!
  - If you see "CONFIRM NUMBER", your mobile number is not yet confirmed. To confirm it:
    1. Click "DELETE NUMBER AND START OVER."
    2. Enter your mobile number (*do not include hyphens/dashes*), to receive a confirmation code.
    3. Enter Confirmation Code (*this will be texted to you*).
    4. Click "CONFIRM NUMBER" and once you see "DONE!" close out the page. You are done!
2. Save the **City of Hope CME text-in number** as a contact in your cell phone: **626-314-7448**
  3. Please ensure your cell phone is fully charged, as charging stations will not be available in the conference area.

## ◆ General Information ◆

## 3rd Annual Southern California Genitourinary Cancer Research Forum

**MEETING MATERIALS**

Check-in at the registration desk to receive conference materials and a name badge.

**CONFERENCE NAME BADGE**

Official conference name badge **must** be worn at all times to gain and maintain access to conference room and meals.

**CONFERENCE LOCATION**

Paséa Hotel & Spa  
21080 Pacific Coast Highway  
Huntington Beach, CA 92648

**EDUCATIONAL SESSIONS**

Sapphire Ballroom

**REGISTRATION DESK - HOURS OF OPERATION**

<i>DATE</i>	<i>TIME</i>	<i>LOCATION</i>
Friday, February 13	8:00 AM – 3:00 PM	Sapphire Ballroom

**CONFERENCE MEALS & BREAKS**

<i>DATE</i>	<i>DESCRIPTION</i>	<i>TIME</i>	<i>LOCATION</i>
Friday, February 13	Breakfast	8:00 – 8:30 AM	Ocean Lawn
Friday, February 13	Refreshment Break	9:50 – 10:30 AM	Sapphire Ballroom
Friday, February 13	Lunch	11:50 AM – 1:30 PM	Ocean Lawn

**EXHIBIT HALL & HOURS**

<i>DATE</i>	<i>TIME</i>	<i>LOCATION</i>
Friday, February 13	8:00 – 8:30 AM; 9:50 – 10:30 AM; 11:50 AM – 1:30 PM	Sapphire Ballroom

## 3rd Annual Southern California Genitourinary Cancer Research Forum

### **Accreditation Statement**

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

### **Credit Designation Statement**

City of Hope designates this live activity for a maximum of 4.25 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the educational activity.

The following may apply *AMA PRA Category 1 Credit*™ for license renewal:

- **Registered Nurses:** Nurses may report up to 4.25 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number.
- **Physician Assistants:** The National Commission on Certification of Physician Assistants states that *AMA PRA Category 1 Credit*™ accredited courses are acceptable for continuing medical education requirements for recertification.

### **Disclosure**

This activity has been planned and implemented in strict compliance with the accreditation requirements, standards and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity. Faculty and Planners have provided written disclosure of all relevant financial relationships which have been included in this handout. Any potential conflicts relative to the disclosure(s) have been resolved. City of Hope further encourages faculty/presenters to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration at first mention and where appropriate in the content. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

## 3rd Annual Southern California Genitourinary Cancer Research Forum

### **Instructions for Obtaining CME Credit (AMA PRA Category 1 Credit™):**

During the conference participants will be provided with a unique attendance code to record their attendance. Physicians and others who wish to receive *AMA PRA Category 1 Credit™* for this activity **must** text in the unique attendance code for this conference, in order to record their attendance.

The unique attendance code will need to be texted to the City of Hope CME text-in number (626-314-7448). If you have not yet saved this number as contact on your cell phone, please do so now, to ensure you are ready to record your attendance. The text-in method will also be facilitated via a QR code that will be available upon check-in, at the conference registration desk.

Credit transcripts will be updated within a week to reflect your participation.

Retrieve your CME Transcripts by visiting the City of Hope CME website: <https://cme.cityofhope.org/>  
Log in using your registered email and password.

### ***Quick Tip!***

Have trouble remembering your password? Once you log in to your account, do not log out, so you do not have to log back in!

Once logged in, click on the My Transcripts section at the top of the page, and click on "Completed Activities". You can then print your Credit Transcript or the individual Certificate, if desired.

For assistance, contact the Department of Continuing Medical Education at 626-218-5622 or [cme@coh.org](mailto:cme@coh.org).

## 3rd Annual Southern California Genitourinary Cancer Research Forum

To ensure that you are receiving the most current slide sets presented, as well as keeping with City of Hope's "green initiative" to reduce waste, an e-syllabus containing slide sets is available for this activity online only (**printed presentation not available on-site**). We recommend you access available presentations prior to the conference and bring your computer or mobile device fully charged. We gratefully acknowledge the presenters for their permission to offer this material as an e-syllabus.

**E-Syllabus Download/Printing Instructions: *(printed syllabus will not be provided on-site)***

If you would like to download or print a copy of available presentations simply:

- 1) Visit the following link: SCGU 2026 | E-Syllabus: <https://cme.cityofhope.org/content/2026-scgu-e-syllabus>
- 2) Find the desired presentation and click on the title of the presentation you would like to download
- 3) The presentation will open and appear in PDF format
- 4) To save the presentation, click "Save As"
- 5) To print the presentation, click "Print"

### AJCC Cancer Staging Forms

- Access to the AJCC Cancer Staging Forms is also available via the e-syllabus.

**PLEASE NOTE:**

- ❖ Some presentations not provided prior to the symposium will be accessible post-activity.
- ❖ All presentations will be available for 4 weeks following the conclusion of this educational activity.
- ❖ Presentations have been uploaded at the discretion of each faculty member.

3rd Annual Southern California  
Genitourinary Cancer Research Forum

# Wi-Fi Network

Network:

Pasea Wireless

Password:

(no password)



◆ Upcoming Conferences ◆

## Upcoming Conferences

Scan QR codes for additional information



**Multidisciplinary Approaches to Cancer Symposium**

**October 1 to 3, 2026**  
The Ritz-Carlton O'ahu, Turtle Bay | Hawaii



**ANNUAL Advances and Innovations in Endoscopic Oncology and Multidisciplinary Gastrointestinal Cancer Care**

**October 23 to 25, 2026**  
Waldorf Astoria Las Vegas, NV





# Acknowledgment of Exhibit Support

City of Hope® gratefully acknowledges the generous support from:

**Astellas**  
**AstraZeneca**  
**AVEO Oncology**  
**Bayer**  
**Eisai Inc**  
**EMD Serono**  
**Exelixis**  
**ImmunityBio**  
**Johnson & Johnson Innovative Medicine**  
**Lantheus**  
**Mdxhealth**  
**Natera**  
**Pfizer Oncology**  
**Sumitomo Pharma America, Inc**  
**Tempus AI**  
**UroGen Pharma**  
**Vertex Pharmaceuticals**



# Sponsorship Acknowledgment

City of Hope® gratefully acknowledges the generous support from:

## **AUDIO VISUAL**

Brought to you by:

## **PLATINUM SPONSORS**

**Bayer**

**Sumitomo Pharma America, Inc**

## **POSTER EXHIBIT SPONSOR**

Brought to you by:

**Natera**



## CORE COMPETENCIES INFORMATION SHEET

### PRACTICE-BASED LEARNING AND IMPROVEMENT

Physicians must be able to investigate and evaluate their patient care practices, appraise and assimilate scientific evidence, and improve their patient care practices. **CME programs address these issues if the topics relate to:**

- analyzing practice experience and performing practice-based improvement activities using a systematic methodology
- locating, appraising, and assimilating evidence from scientific studies related to their patients' health problems
- obtaining and using information about their own population of patients and the larger population from which their patients are drawn
- applying knowledge of study designs and statistical methods to the appraisal of clinical studies and other information on diagnostic and therapeutic effectiveness
- using information technology to manage information, access on-line medical information; and support their own education
- facilitating the learning of students and other health care professionals

### PATIENT CARE

Physicians must be able to provide patient care that is compassionate, appropriate, and effective for the treatment of health problems and the promotion of health. **CME programs address these issues if they address topics related to:**

- The ability to communicate effectively and demonstrate caring and respectful behaviors when interacting with patients and their families;
- gathering essential and accurate information about their patients
- making informed decisions about diagnostic and therapeutic interventions based on patient information and preferences, up-to-date scientific evidence, and clinical judgment
- developing and carrying out patient management plans
- counseling and educating patients and their families
- using information technology to support patient care decisions and patient education
- performing competently all medical and invasive procedures considered essential for the area of practice
- providing health care services aimed at preventing health problems or maintaining health
- working with health care professionals, including those from other disciplines, to provide patient-focused care

### SYSTEMS-BASED PRACTICE

Physicians must demonstrate an awareness of and responsiveness to the larger context and system of health care and the ability to effectively call on system resources to provide care that is of optimal value. **CME programs address these issues if the topics relate to:**

- understanding how their patient care and other professional practices affect other health care professionals, the health care organization, and the larger society and how these elements of the system affect their own practice
- knowing how types of medical practice and delivery systems differ from one another, including methods of controlling health care costs and allocating resources
- practicing cost-effective health care and resource allocation that does not compromise quality of care
- advocating for quality patient care and assisting patients in dealing with system complexities
- knowing how to partner with health care managers and health care providers to assess, coordinate, and improve health care and knowing how these activities can affect system performance

### MEDICAL KNOWLEDGE

Physicians must demonstrate knowledge about established and evolving biomedical, clinical, and cognate (e.g. epidemiological and social-behavioral) sciences and the application of this knowledge to patient care. **CME programs address these issues if the topics relate to:**

- demonstration of an investigatory and analytic thinking approach to clinical situations
- knowledge and application of the basic and clinically supportive sciences which are appropriate to their discipline

### INTERPERSONAL AND COMMUNICATION SKILLS

Physicians must be able to demonstrate interpersonal and communication skills that result in effective information exchange and teaming with patients, their patients families, and professional associates. **CME programs address these issues if the topics relate to:**

- creating and sustaining a therapeutic and ethically sound relationship with patients
- using effective listening skills and eliciting and providing information using effective nonverbal, explanatory, questioning, and writing skills
- working effectively with others as a member or leader of a health care team or other professional group

### PROFESSIONALISM

Physicians must demonstrate a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity to a diverse patient population. **CME programs address these issues if the topics relate to:**

- demonstrating respect, compassion, and integrity; responsiveness to the needs of patients and society that supersedes self-interest; accountability to patients, society, and the profession; and a commitment to excellence and on-going professional development
- demonstrating a commitment to ethical principles pertaining to provision or withholding of clinical care, confidentiality of patient information, informed consent, and business practices
- demonstrating sensitivity and responsiveness to patients' culture, age, gender, and disabilities



◆ Department of Continuing Medical Education ◆

**Conflict of Interest Disclosure and Resolution & Core Competencies  
3rd Annual Southern California Genitourinary Cancer Research Forum  
February 13, 2026**

City of Hope takes responsibility for the content, quality, and scientific integrity of this CME activity.

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the [Standards for Integrity and Independence in Accredited Continuing Education](#) of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships<sup>1</sup> with any ineligible company<sup>2</sup>. To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. Presentations will be provided to participants as an e-syllabus or in a meeting handout, all relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

**CORE COMPETENCIES**

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Practice-Based Learning and Improvement, (2) Patient Care, (3) Systems-Based Practice, (4) Medical Knowledge, (5) Interpersonal and Communication Skills, and (6) Professionalism. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below. CME certificates for this activity will reflect those core competencies addressed by the educational content of the overall conference.

<b>Conference Faculty</b>	<b>Commercial Interest</b>	<b>Conflict/ Resolution &amp; Faculty Discussion of Off-Label Drugs</b>	<b>Core Competencies</b>
Nikita V. Baclig, MD, MPH	I do not have any relevant financial relationships with any ineligible companies.	<i>Off-label/Investigational use of:</i> Nexus ADC for Nectin-4, Vepugratinib, Relatlimab/Nivolumab (MODERN trial), Dato-DXD	1 & 4
Aditya Bagrodia, MD	Consultant for Ferring, Urogen, and Veracyte.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1
Leslie Ballas, MD	Consultant for MDxHealth.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	2, 3 & 4
David J. Benjamin, MD	Consultant for AIMED BIO, Astellas, AVEO Oncology, Bayer, Dendreon, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Janssen, Janux, Merck KGAA and Seagen; On the Speakers Bureau for Merck Sharpe Dohme.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of:</i> INV-9956 (as part of phase I trial at Hoag), JANX007 (as part of phase I trial at Hoag)	1, 3, 4, 5 & 6
Alex Chehrazi-Raffle, MD	Consultant for Aveo, Inc., Eisai Inc., Exelixis Inc., and Pfizer, Inc.; Grant/Research Support from Tempus AI, Dendreon Pharmaceuticals LLC, and Fennec Pharmaceuticals Inc.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Moderator 4

<b>Conference Faculty</b>	<b>Commercial Interest</b>	<b>Conflict/ Resolution &amp; Faculty Discussion of Off-Label Drugs</b>	<b>Core Competencies</b>
Yu-Wei Chen, MD, MS	Consultant for Eisai and Johnson & Johnson.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Sia Daneshmand, MD	Consultant for AstraZeneca, Bristol-Myers Squibb, CG Oncology, Engene, Ferring, Immunitybio, Johnson and Johnson, Pacific Edge, Pfizer, Photocure, Protara, Urogen, and Vesica Health.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Tanya Barauskas Dorff, MD	Consultant for Abbvie, Bayer, BlueEarth, Janssen, Johnson and Johnson, Novartis, and Pfizer; Research/Grant Support from Amgen, AstraZeneca, and Dendreon.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Xaluritamig, PSCA CAR T, STEAP2 CAR T, pasritamig, luxdegalutamide, abbv-969, CEA immunocytokine, Ac225-CEA, and Ac225-PSMA</i>	Moderator 1, 2 & 6
Jun Gong, MD	Consultant for Agenus, AstraZeneca, Bayer, BeOne, Eisai, Genentech, Incyte, Pfizer, Seagen, and Taiho.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Hyung Kim, MD	Consultant for Dendreon; Other Financial Relationship – License through Crown Bioscience.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	2 & 4
Amar U. Kishan, MD	Consultant for Lantheus and Novartis; Grant/Research Support from Artera, Lantheus, Novartis, and ViewRay Systems; Stock/Shareholder for MiraDx.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Daneng Li, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Nataliya Mar, MD	Grant/Research Support for Gilead. Consultant for Pfizer, EMD Serono, and Johnson & Johnson. On the Speakers Bureau for Eisai and Merck	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Rana R. McKay, MD	Consultant for Ambrx, Arcus, AstraZeneca, Aveo, Bayer, Blue Earth Diagnostics, Bristol-Myers Squibb, Calithera, Caris, Daiichi Sankyo, Dendreon, Exelixis, Johnson & Johnson, Lilly, Merck, Myovant, Neomorph, Nimbus, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, and Tempus	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Sumanta K. Pal, MD	Consultant for Adicet Bio, Arsenal Bio, CRISPR Therapeutics, Exelixis, Genentech, Merck, Miyarisan Pharmaceutical, Osel, Xencor; On the Speakers Bureau for IntrinsiQ, MJH Life Sciences, and PeerView.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Planner Moderator 1, 2, 3, 4, 5 & 6
Thomas Powles, MD, MRCP	Consultant for AstraZeneca, Bristol-Myers Squibb, Exelixis, Ipsen, MSD, Novartis, Pfizer, Astellas, Eisai, and Roche.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Arash Rezazadeh, MD	Consultant for AimedBio, Amgen, AstraZeneca, AVEO Oncology, Bayer, Bicycle Therapeutics, Bristol-Myers Squibb, Eisai, EMD Serono, Exelixis, Gilead Sciences, Janssen, Myovant Sciences, Pfizer, Sanofi, Sumitomo Pharma Oncology; On the Speaker's Bureau for Amgen, AVEO Oncology, Bayer, Bristol-Myers Squibb, Eisai, EMD Serono, Exelixis, Gilead Sciences, Janssen, Myovant Sciences, Pfizer, and Sanofi; Grant/Research Support from Amgen, Arvinas, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Eikon Therapeutics, Exelixis, Genentech, Immunomedics, Janssen, Merck, Mirati, Navir, Novartis, POINT Biopharma, and Seattle Genetics	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Xaluritamig</i>	1, 3, 4, 5 & 6
Brian Rini, MD	Consultant for Eisai, Formedics, and Merck.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 3, 4, 5 & 6
Crystal Saavedra, BA	I do not have any relevant financial relationships with any ineligible companies.	None	Planner
John Shin, MD	I do not have any relevant financial relationships with any ineligible companies.	None	4
Brian Shuch, MD	Consultant for Merck, Veracyte, and Telix; On the Speakers Bureau for Histosonic.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1 & 4
Abhishek Tripathi, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Przemyslaw Twardowski, MD	On the Speakers Bureau for Astellas, Bayer, Johnson & Johnson, Novartis, and Pfizer.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Saruparib, TLX-591, and 225 Ac-PSMA-617</i>	1, 2, 3 & 4
Wesley Yip, MD	Consultant for Telix. Grant/Research Support from Merck and Pfizer.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	2, 4 & 6

1. The ACCME defines "relevant" financial relationships" as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.
2. The ACCME defines an "Ineligible company" as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

## 3rd Annual Southern California Genitourinary Cancer Research Forum

FRIDAY, FEBRUARY 13, 2026

8:00 – 8:30 AM	<b>REGISTRATION/BREAKFAST/EXHIBITS/POSTERS</b>
8:30 – 8:40 AM	<b>Introduction to the 3<sup>rd</sup> Annual Southern California Genitourinary Cancer Research Forum</b> Sumanta K. Pal, MD   City of Hope Sia Daneshmand, MD   University of Southern California
8:40 – 9:00 AM	<b>Key Updates in Kidney Cancer</b> Rana R. McKay, MD   Moores Cancer Center, University of California San Diego
9:00 – 9:50 AM	<b>Case-Based Trial Discussion:</b> <ul style="list-style-type: none"><li>• <b>Localized Renal Cell Carcinoma (RCC)</b></li><li>• <b>Front-line RCC</b></li><li>• <b>Salvage RCC</b></li><li>• <b>Non-Clear Cell RCC</b></li></ul> <i>Moderator:</i> Sumanta K. Pal, MD   City of Hope Yu-Wei Chen, MD, MS   University of California San Diego Nataliya Mar, MD   University of California Irvine Brian Shuch, MD   UCLA Institute of Urologic Oncology Hyung Kim, MD   Cedars-Sinai Medical Center Wesley Yip, MD   City of Hope
9:50 – 10:30 AM	<b>REFRESHMENT BREAK/EXHIBITS/POSTERS</b>
10:30 – 10:50 AM	<b>Key Updates in Urothelial Cancer</b> Abhishek Tripathi, MD   City of Hope
10:50 – 11:40 AM	<b>Panel: Bladder Cancer Studies</b> <ul style="list-style-type: none"><li>• <b>Non-Muscle Invasive Bladder Cancer (NMIBC)</b></li><li>• <b>Muscle Invasive Bladder Cancer (MIBC)</b></li><li>• <b>Metastatic, 1st</b></li><li>• <b>Metastatic, Salvage</b></li></ul> <i>Moderator:</i> Sia Daneshmand, MD   University of Southern California Aditya Bagrodia, MD   University of California San Diego Nataliya Mar, MD   University of California Irvine Leslie Ballas, MD   Cedars-Sinai Medical Center Nikita V. Baclig, MD, MPH   University of California Los Angeles Abhishek Tripathi, MD   City of Hope
11:40 – 11:50 AM	<b>GROUP PICTURE</b>
11:50 AM – 1:30 PM	<b>LUNCH/EXHIBITS/POSTERS</b>

1:30 – 1:50 PM

**Key Updates in Prostate Cancer**

Jun Gong, MD | Cedars-Sinai Medical Center

1:50 – 2:35 PM

**Panel: Prostate Cancer Studies**

- **Localized**
- **Salvage Radiotherapy/Biochemical Recurrence (BCR)**
- **Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)**
- **Metastatic Castration-Resistant Prostate Cancer (mCRPC)**

*Moderator:* Tanya Barauskas Dorff, MD | City of Hope

Arash Rezazadeh, MD | University of California Irvine

Amar U. Kishan, MD | University of California Los Angeles

John Shin, MD | Loma Linda University Health

David J. Benjamin, MD | Hoag Family Cancer Institute

Przemyslaw Twardowski, MD | Providence Saint John's Health Center

Alex Chehrazi-Raffle, MD | City of Hope

2:35 – 3:00 PM

**Summary of Thoughts from the Uromigos**

Thomas Powles, MD, MRCP | Barts Cancer Centre at St Bartholomew's Hospital

Brian Rini, MD | Vanderbilt University Medical Center

3:00 PM

**ADJOURN FORUM**

## 3rd Annual Southern California Genitourinary Cancer Research Forum

### TASKS:

**Conference Evaluation opens February 13, 2026, at 3pm:**

<https://cme.cityofhope.org//node/18952/course-object/45899>

**Conference Feedback opens February 13, 2026, at 3pm:**

<https://cme.cityofhope.org//node/18952/course-object/45900>

### **IMPORTANT:**

*Last day to complete Conference Tasks is: **February 20, 2026***

You can scan the QR Code below to complete the tasks on your mobile device once the conference adjourns,  
starting on 2/13/2026 at 3pm

